Bayer AG and Algeta ASA won U.S. approval for their drug to treat an advanced form of prostate cancer that doesn’t respond to the standard testosterone-lowering treatments.
The Food and Drug Administration cleared the medicine more than three months early for patients whose disease has spread to their bones, the agency said in a statement today. The drug, Xofigo, is designed treat the secondary cancer that has settled in the bones. Prostate cancer is the most common cancer among men after skin cancer, according to the American Cancer Society.
The injection, also known as radium-223, has similar properties to calcium and is drawn to bones, Oslo-based Algeta said on its website. The injection may generate $802 million in sales in 2017, according to the average of six analysts’estimates compiled by Bloomberg.
“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” Richard Pazdur, director of the FDA’s Office of Hematology and Oncology Products, said in the statement. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”
This drug looks like real targeted medicine. Just one question is unclear for me: how this drug will be distributed?
No comments:
Post a Comment